{"url_path":"/sec/btai/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1720893/0001104659-26-061769-index.html","accession_number":"0001104659-26-061769","cik":"0001720893","ticker":"BTAI","issuer_name":"BioXcel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1720893/0001104659-26-061769-index.html","primary_entity_key":"0001720893","primary_entity_name":"BioXcel Therapeutics, Inc."},"word_count":61,"has_tables":true,"body_markdown":"Item 5. Other Information\n\n(a) None.\n\n(b) None.\n\n(c) During the three months ended March 31, 2026, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.\n\n​\n\n136\n\n[Table of Contents](#TOC)"}